Role of old antibiotics in multidrug resistant bacterial infections

Current Drug Targets

Volumn 10, Issue 9, 2009, Pages 895-905

  Maviglia, R ^a   Nestorini, R ^a   Pennisi, M A ^a  

^a CATHOLIC UNIVERSITY   (Italy)

Author keywords

Chloramphenicol; Fosfomycin; Fusidic acid; Isepamicin; Multidrug bacteria infections; Old antibiotics; Polymyxins; Rifampicin

Indexed keywords

AMIKACIN; AMINOGLYCOSIDE ANTIBIOTIC AGENT; AMOXICILLIN PLUS CLAVULANIC ACID; ANTIBIOTIC AGENT; BETA LACTAM ANTIBIOTIC; CEFALOTIN; CEFTAZIDIME; CEPHALOSPORIN DERIVATIVE; CHLORAMPHENICOL; COLISTIMETHATE; COLISTIN; COTRIMOXAZOLE; DALFOPRISTIN PLUS QUINUPRISTIN; ETHAMBUTOL; FOSFOMYCIN; FUSIDIC ACID; GENTAMICIN; IMIPENEM; ISEPAMICIN; ISONIAZID; LINEZOLID; MONOBACTAM DERIVATIVE; NITROFURANTOIN; PENICILLIN DERIVATIVE; POLYMYXIN; POLYMYXIN B; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RIFAMPICIN; STREPTOMYCIN; UNINDEXED DRUG;

ACINETOBACTER BAUMANNII; ACINETOBACTER INFECTION; ANTIBACTERIAL ACTIVITY; ANTIBIOTIC SENSITIVITY; APLASTIC ANEMIA; ASEPTIC MENINGITIS; BACTERIAL ENDOCARDITIS; BACTERIAL INFECTION; BACTERIAL MENINGITIS; BACTERIAL PNEUMONIA; BACTERIAL SKIN DISEASE; BONE INFECTION; CLINICAL TRIAL; CONTINUOUS INFUSION; CRITICALLY ILL PATIENT; CYSTIC FIBROSIS; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG EFFICACY; DRUG HALF LIFE; DRUG MECHANISM; DRUG METABOLISM; DRUG PENETRATION; DRUG POTENTIATION; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; ENTEROCOCCAL INFECTION; GONORRHEA; GRAM NEGATIVE INFECTION; GRAM POSITIVE INFECTION; HAEMOPHILUS INFECTION; HOSPITAL INFECTION; HUMAN; INFECTIOUS ARTHRITIS; INTENSIVE CARE UNIT; KIDNEY FAILURE; LEGIONNAIRE DISEASE; LISTERIOSIS; LOWER RESPIRATORY TRACT INFECTION; LUNG INFECTION; MENINGITIS; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS INFECTION; MINIMUM INHIBITORY CONCENTRATION; MORTALITY; MULTIDRUG RESISTANCE; MYCOBACTERIOSIS; NEPHROTOXICITY; NEUROTOXICITY; NONHUMAN; PARESTHESIA; PHARMACODYNAMICS; PNEUMONIA; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTION; PYREXIA IDIOPATHICA; RECOMMENDED DRUG DOSE; REVIEW; SEPSIS; SEPTIC SHOCK; SKIN INFECTION; SOFT TISSUE INFECTION; STAPHYLOCOCCUS INFECTION; TUBERCULOSIS; URINARY TRACT INFECTION; VANCOMYCIN RESISTANT ENTEROCOCCUS; VENTILATOR ASSOCIATED PNEUMONIA;

ANTI-BACTERIAL AGENTS; BACTERIAL INFECTIONS; DRUG RESISTANCE, MICROBIAL; DRUG RESISTANCE, MULTIPLE; HUMANS;

EID: 70450199336     PISSN: 13894501     EISSN: None     Source Type: Journal    
DOI: 10.2174/138945009789108846     Document Type: Review

References (108)

1. Weber DJ, Raasch R, Rutala WA Nosocomial infections in the ICU: the growing importance of antibiotic-resistant pathogens. Chest 1999; 115: 34S-41S. (Pubitemid 29133435)
2. Jones ME, Draghi DC, Thornsberry C, Karlowsky JA, Sahm DF, Wenzel RP. Emerging resistance among bacterial pathogens in the intensive care unit - a European and North American Surveillance study (2000-2002). Ann Clin Microbiol Antimicrob 2004; 3: 14.
3. Fagon JY, Chastre J, Domart Y, Trouillet JL, Pierre J, Darne C, et al. Nosocomial pneumonia in patients receiving continuous mechanical ventilation. Prospective analysis of 52 episodes with use of a protected specimen brush and quantitative culture techniques. Am Rev Respir Dis 1989; 139: 877-884
4. Fagon JY, Chastre J, Hance AJ, Montravers P, Novara A, Gibert C. Nosocomial pneumonia in ventilated patients: a cohort study evaluating attributable mortality and hospital stay. Am J Med 1993; 94: 281-288
5. Rello J, Ausina V, Ricart M, Castella J, Prats G. Impact of previous antimicrobial therapy on the etiology and outcome of ventilator-associated pneumonia. Chest 1993; 104: 1230-1235 (Pubitemid 23306084)
6. Rello J, Rué M, Jubert P, Muses G, Soñora R, Vallés J, et al. Survival in patients with Nosocomial pneumonia: impact of the severity of illness and the etiologic agent. Crit Care Med 1997; 25: 1862-1867
7. Kumar A, Roberts D, Wood KE, Light B, Parrillo JE, Sharma S, et al. Duration of hypotension before initiation of effective antimicrobial therapy is the critical determinant of survival in human septic shock. Crit Care Med 2006; 34: 1589-1596 (Pubitemid 43810035)
8. Kollef KE, Schramm GE, Wills AR, Reichley RM, Micek ST, Kollef MH. Predictors of 30-day mortality and hospital costs in patients with ventilator-associated pneumonia attributed to potentially antibiotic-resistant gram-negative bacteria. Chest 2008; 134: 281-287
9. Kollef MH, Sherman G, Ward S, Fraser VJ. Inadequate antimicrobial treatment of infections: a risk factor for hospital mortality among critically ill patients. Chest 1999; 115: 462-474 (Pubitemid 29083057)
10. Schwaber MJ, Navon-Venezia S, Kaye KS, Ben-Ami R, Schwartz D, Carmeli Y. Clinical and economic impact of bacteremia with extended- spectrum-beta- lactamase-producing Enterobacteriaceae. Antimicrob Agents Chemother 2006; 50: 1257-1262
11. Bratu S, Landman D, Haag R, Recco R, Eramo A, Alam M, et al. Rapid spread of carbapenem-resistant Klebsiella pneumoniae in New York City: a new threat to our antibiotic armamentarium. Arch Intern Med 2005; 165: 1430-1435
12. Kwon KT, Oh WS, Song JH, Chang HH, Jung SI, Kim SW, et al. Impact of imipenem resistance on mortality in patients with Acinetobacter bacteraemia. J Antimicrob Chemother 2007; 59: 525-530
13. Sunenshine RH, Wright MO, Maragakis LL, Harris AD, Song X, Hebden J, et al. Multidrug-resistant Acinetobacter infection mortality rate and length of hospitalization. Emerg Infect Dis 2007; 13: 97-103. (Pubitemid 46057843)
14. Lee NY, Lee HC, Ko NY, Chang CM, Shih HI, Wu CJ, et al. Clinical and economic impact of multidrug resistance in nosocomial Acinetobacter baumannii bacteremia. Infect Control Hosp Epidemiol 2007; 28: 713-719
15. Peleg AY, Adams J, Paterson DL. Tigecycline efflux as a mechanism for nonsusceptibility in Acinetobacter baumannii. Antimicrob Agents Chemother 2007; 51: 2065-2069
16. Rice LB. Federal funding for the study of antimicrobial resistance in nosocomial pathogens: no ESKAPE. J Infect Dis 2008; 197: 1079-1081
17. Paterson DL. The epidemiological profile of infections with multidrug-resistant Pseudomonas aeruginosa and Acinetobacter species. Clin Infect Dis 2006; 43: S43-8.
18. Boucher HW, Talbot GH, Bradley JS, Edwards JE, Gilbert D, Rice LB, et al. Bad bugs, no drugs: no ESKAPE! An update from the Infectious Diseases Society of America. Clin Infect Dis 2009; 48: 1-12.
19. Falagas ME, Rafailidis PI, Kasiakou SK, Hatzopoulou P, Michalopoulos A. Effectiveness and nephrotoxicity of colistin monotherapy vs. colistin-meropenem combination therapy for multidrug-resistant Gram-negative bacterial infections. Clin Microbiol Infect 2006; 12: 1227-1230 (Pubitemid 44762527)
20. Hawkey PM. Pre-clinical experience with daptomycin. J Antimicrob Chemother 2008; 62: iii7-14.
21. Treviño M, Martínez-Lamas L, Romero-Jung PA, Giráldez JM, Alvarez-Escudero J, Regueiro BJ. Endemic linezolid-resistant Staphylococcus epidermidis in a critical care unit. Eur J Clin Microbiol Infect Dis 28: 527-533
22. Erlandson KM, Sun J, Iwen PC, Rupp ME. Impact of the more-potent antibiotics quinupristin-dalfopristin and linezolid on outcome measure of patients with vancomycin-resistant Enterococcus bacteremia. Clin Infect Dis 2008; 46: 30-36 (Pubitemid 351263556)
23. Bishop E, Melvani S, Howden BP, Charles PG, Grayson ML. Good clinical outcomes but high rates of adverse reactions during linezolid therapy for serious infections: a proposed protocol for monitoring therapy in complex patients. Antimicrob Agents Chemother 2006; 50: 1599-1602
24. Kwa AL, Tam VH, Falagas ME. Polymyxins: a review of the current status including recent developments. Ann Acad Med Singapore 2008; 37: 870-883
25. Falagas ME, Kasiakou SK Colistin: the revival of polymyxins for the management of multidrug-resistant gram-negative bacterial infections. Clin Infect Dis 2005; 40: 1333-1341
26. Li J, Nation RL, Milne RW, Turnidge JD, Coulthard K. Evaluation of colistin as an agent against multi-resistant Gram-negative bacteria. Int J Antimicrob Agents 2005; 25: 11-25. (Pubitemid 40023341)
27. Evans ME, Feola DJ, Rapp RP. Polymyxin B sulfate and colistin: old antibiotics for emerging multiresistant gram-negative bacteria. Ann Pharmacother 1999; 33: 960-967
28. Bergen PJ, Li J, Rayner CR, Nation RL. Colistin methanesulfonate is an inactive prodrug of colistin against Pseudomonas aeruginosa. Antimicrob Agents Chemother 2006; 50: 1953-1958
29. Gales AC, Reis AO, Jones RN. Contemporary assessment of antimicrobial susceptibility testing methods for polymyxin B and colistin: review of available interpretative criteria and quality control guidelines. J Clin Microbiol 2001; 39: 183-190
30. Hogardt M, Schmoldt S, Götzfried M, Adler K, Heesemann J. Pitfalls of polymyxin antimicrobial susceptibility testing of Pseudomonas aeruginosa isolated from cystic fibrosis patients. J Antimicrob Chemother 2004; 54: 1057-1061
31. Mortensen NP, Fowlkes JD, Sullivan CJ, Allison DP, Larsen NB, Molin S, et al. Effects of colistin on surface ultrastructure and nanomechanics of Pseudomonas aeruginosa cells. Langmuir 2009; 25: 3728-3733.
32. Young ML, Bains M, Bell A, Hancock RE. Role of Pseudomonas aeruginosa outer membrane protein OprH in polymyxin and gentamicin resistance: isolation of an OprH-deficient mutant by gene replacement techniques. Antimicrob Agents Chemother 1992; 36: 2566-2568
33. Winfield MD, Latifi T, Groisman EA. Transcriptional regulation of the 4-amino-4-deoxy-L-arabinose biosynthetic genes in Yersinia pestis. J Biol Chem 2005; 280: 14765-14772 (Pubitemid 40562824)
34. Bengoechea JA, Skurnik M. Temperature-regulated efflux pump/potassium antiporter system mediates resistance to cationic antimicrobial peptides in Yersinia. Mol Microbiol 2000; 37: 67-80. (Pubitemid 30479358)
35. Ito-Kagawa M, Koyama Y. Selective cleavage of a peptide antibiotic, colistin by colistinase. J Antibiot (Tokyo) 1980; 33: 1551-1555 (Pubitemid 11186876)
36. Matthaiou DK, Michalopoulos A, Rafailidis PI, Karageorgopoulos DE, Papaioannou V, Ntani G, et al. Risk factors associated with the isolation of colistin-resistant gram-negative bacteria: a matched case-control study. Crit Care Med 2008; 36: 807-811
37. Li J, Milne RW, Nation RL, Turnidge JD, Coulthard K Stability of colistin and colistin methanesulfonate in aqueous media and plasma as determined by high-performance liquid chromatography. Antimicrob Agents Chemother 2003; 47: 1364-1370 (Pubitemid 36368598)
38. Kwa A, Kasiakou SK, Tam VH, Falagas ME. Polymyxin B: similarities to and differences from colistin (polymyxin E). Expert Rev Anti Infect Ther 2007; 5: 811-821
39. Froman J, Gross L, Curatola S Serum and urine levels following parenteral administration of sodium colistimethate to normal individuals. J Urol 1970; 103: 210-214
40. Li J, Coulthard K, Milne R, Nation RL, Conway S, Peckham D, et al. Steady-state pharmacokinetics of intravenous colistin methane-sulphonate in patients with cystic fibrosis. J Antimicrob Chemother 2003; 52: 987-992 (Pubitemid 38008420)
41. Li J, Rayner CR, Nation RL, Deans R, Boots R, Widdecombe N, et al. Pharmacokinetics of colistin methanesulfonate and colistin in a critically ill patient receiving continuous venovenous hemodiafiltration. Antimicrob Agents Chemother 2005; 49: 4814-4815 (Pubitemid 41552630)
42. Goodwin NJ, Friedman EA. The effects of renal impairment, peritoneal dialysis, and hemodialysis on serum sodium colistimethate levels. Ann Intern Med 1968; 68: 984-994
43. Greenberg PA, Sanford JP. Removal and absorption of antibiotics in patients with renal failure undergoing peritoneal dialysis. Tetracycline, chloramphenicol, kanamycin, and colistimethate. Ann Intern Med 1967; 66: 465-470
44. Falagas ME, Bliziotis IA, Tam VH Intraventricular or intrathecal use of polymyxins in patients with Gram-negative meningitis: a systematic review of the available evidence. Int J Antimicrob Agents 2007; 29: 9-25.
45. American Thoracic Society; Infectious Diseases Society of America. Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia. Am J Respir Crit Care Med 2005; 171: 388-416. (Pubitemid 40227463)
46. Tan CH, Li J, Nation RL. Activity of colistin against heteroresistant Acinetobacter baumannii and emergence of resistance in an in vitro pharmacokinetic/pharmacodynamic model. Antimicrob Agents Chemother 2007; 51: 3413-3415 . (Pubitemid 47073453)
47. Owen RJ, Li J, Nation RL, Spelman D. In vitro pharmacodynamics of colistin against Acinetobacter baumannii clinical isolates. J Antimicrob Chemother 2007; 59: 473-477
48. Gunderson BW, Ibrahim KH, Hovde LB, Fromm TL, Reed MD, Rotschafer JC. Synergistic activity of colistin and ceftazidime against multiantibiotic- resistant Pseudomonas aeruginosa in an in vitro pharmacodynamic model. Antimicrob Agents Chemother 2003; 47: 905-909
49. Kroeger LA, Hovde LB, Mitropoulos IF, Schafer J, Rotschafer JC. Colistin methanesulfonate against multidrug-resistant Acinetobacter baumannii in an in vitro pharmacodynamic model. Antimicrob Agents Chemother 2007; 51: 3431-3433
50. Levin AS, Barone AA, Penço J, Santos MV, Marinho IS, Arruda EA, et al. Intravenous colistin as therapy for nosocomial infections caused by multidrug-resistant Pseudomonas aeruginosa and Acinetobacter baumannii. Clin Infect Dis 1999; 28: 1008-1011 (Pubitemid 29203530)
51. Garnacho-Montero J, Ortiz-Leyba C, Jiménez-Jiménez FJ, Barrero-Almodóvar AE, García-Garmendia JL, Bernabeu-WittelI M, et al. Treatment of multidrug-resistant Acinetobacter baumannii ventilator-associated pneumonia (VAP) with intravenous colistin: a comparison with imipenem-susceptible VAP. Clin Infect Dis 2003; 36: 1111-1118
52. Reina R, Estenssoro E, Sáenz G, Canales HS, Gonzalvo R, Vidal G, et al. Safety and efficacy of colistin in Acinetobacter and Pseudomonas infections: a prospective cohort study. Intens Care Med 2005; 31: 1058-1065 (Pubitemid 41125336)
53. Michalopoulos A, Kasiakou SK, Rosmarakis ES, Falagas ME Cure of multidrug-resistant Acinetobacter baumannii bacteraemia with continuous intravenous infusion of colistin. Scand J Infect Dis 2005; 37: 142-145
54. Hanasawa K, Tani T, Kodama M. New approach to endotoxic and septic shock by means of polymyxin B immobilized fiber. Surg Gynecol Obstet 1989; 168: 323-331 (Pubitemid 19120570)
55. Sato T, Shoji H, Koga N. Endotoxin adsorption by polymyxin B immobilized fiber column in patients with systemic inflammatory response syndrome: the Japanese experience. Ther Apher Dial. 2003; 7: 252-258 (Pubitemid 36753925)
56. Tani T, Hanasawa K, Kodama M. [Usefulness of endotoxin removal from the septic blood with direct hemoperfusion using PMX-F] Nippon Geka Gakkai Zasshi 1989; 90: 1370-1373
57. Cruz DN, Perazella MA, Bellomo R, de Cal M, Polanco N, Corradi V, et al. Effectiveness of polymyxin B-immobilized fiber column in sepsis: a systematic review. Crit Care 2007; 11: R47. (Pubitemid 46805281)
58. Høiby N, Frederiksen B, Pressler T. Eradication of early Pseudomonas aeruginosa infection. J Cyst Fibros 2005; 4: 49-54.
59. Littlewood JM, Miller MG, Ghoneim AT, Ramsden CH Nebulised colomycin for early pseudomonas colonisation in cystic fibrosis. Lancet 1985; 1: 865.
60. Conway SP Nebulized antibiotic therapy: the evidence. Chron Respir Dis 2005; 2: 35-41.
61. Falagas ME, Siempos II, Rafailidis PI, Korbila IP, Ioannidou E, Michalopoulos A Inhaled colistin as monotherapy for multidrug-resistant gram (-) Nosocomial pneumonia: a case series. Respir Med 2009; 103: 707-713
62. Tallgren LG, Liewendahl K, Kuhlbaeck B The thrrapeutic success and nephrotoxicity of colistin in acute and chronic nephropathies with impaired renal function. Acta Med Scand 1965; 177: 717-728
63. Koch-Weser J, Sidel VW, Federman EB, Kanarek P, Finer DC, Eaton AE Adverse effects of sodium colistimethate. Manifestations and specific reaction rates during 317 courses of therapy. Ann Intern Med 1970; 72: 857-868
64. Fekety FR Jr, Norman PS, Cluff LE The treatment of gram-negative bacillary infections with colistin. The toxicity and efficacy of large doses in forty-eight patients. Ann Intern Med 1962; 57: 214-229
65. Olesen S, Madsen PO Methacycline in the treatment of urinary tract infections. Curr Ther Res Clin Exp 1967; 9: 595-599
66. Baines RD Jr, Rifkind D. Intravenous administration of sodium colistimethate. JAMA 1964; 190: 278-281
67. Michalopoulos AS, Tsiodras S, Rellos K, Mentzelopoulos S, Falagas ME. Colistin treatment in patients with ICU-acquired infections caused by multiresistant Gram-negative bacteria: the renaissance of an old antibiotic. Clin Microbiol Infect 2005; 11: 115-121 (Pubitemid 40259694)
68. Markou N, Apostolakos H, Koumoudiou C, Athanasiou M, Koutsoukou A, Alamanos I, et al. Intravenous colistin in the treatment of sepsis from multiresistant Gram-negative bacilli in critically ill patients. Crit Care 2003; 7: R78-83.
69. Berg JR, Spilker CM, Lewis SA. Modulation of polymyxin B effects on mammalian urinary bladder. Am J Physiol 1998; 275: F204-15.
70. Berg JR, Spilker CM, Lewis SA Effects of polymyxin B on mammalian urinary bladder. J Membr Biol 1996; 154: 119-130 (Pubitemid 26413995)
71. Hoeprich PD. The polymyxins. Med Clin North Am 1970; 54: 1257-1265
72. Koch-Weser J, Sidel VW, Federman EB, Kanarek P, Finer DC, Eaton AE. Adverse effects of sodium colistimethate. Manifestations and specific reaction rates during 317 courses of therapy. Ann Intern Med 1970; 72: 857-868
73. Fekety FR Jr, Norman PS, Cluff LE. The treatment of gram-negative bacillary infections with colistin. The toxicity and efficacy of large doses in forty-eight patients. Ann Intern Med 1962; 57: 214-229
74. Duncan DA. Colistin toxicity. Neuromuscular and renal manifestations. Two cases treated by hemodialysis. Minn Med 1973; 56: 31-5..
75. Zauder HL, Barton N, Bennett EJ, Lore J. Colistimethate as a cause of postoperative apnoea. Can Anaesth Soc J 1966; 13: 607-610
76. Sabawala PB, Dillon JB The action of some antibiotics on the human intercostal nerve-muscle complex. Anesthesiology 1959; 20: 659-668
77. Woodyer RD, Shao Z, Thomas PM, Kelleher NL, Blodgett JA, Metcalf WW, et al. Heterologous production of fosfomycin and identification of the minimal biosynthetic gene cluster. Chem Biol 2006; 13: 1171-1182 (Pubitemid 44750729)
78. Joukhadar C, Klein N, Dittrich P, Zeitlinger M, Geppert A, Skhirtladze K, et al. Target site penetration of fosfomycin in critically ill patients. J Antimicrob Chemother 2003; 51: 1247-1252 (Pubitemid 36622081)
79. Schmitz FJ, Geisel R, Wagner S, Lenz W, Kamla V, Heinz HP, et al. Typing, resistance behavior and occurrence of methicillin-resistant Staphylococcus aureus strains in a surgical intensive care unit] Zentralbl Hyg Umweltmed 1996; 198: 355-380
80. Traub WH, Scheidhauer R, Leonhard B, Bauer D Surveillance of Pseudomonas aeruginosa in intensive care units: clusters of nosocomial cross-infection and encounter of a multiple-antibiotic resistant strain. Chemotherapy 1998; 44: 243-259
81. Shrestha NK, Chua JD, Tuohy MJ, Wilson DA, Procop GW, Longworth DL, et al. Antimicrobial susceptibility of vancomycin-resistant Enterococcus faecium: potential utility of fosfomycin. Scand J Infect Dis 2003; 35: 12-14
82. Tod M, Padoin C, Petitjean O Clinical pharmacokinetics and pharmacodynamics of isepamicin. Clin Pharmacokinet 2000; 38: 205-223 (Pubitemid 30156622)
83. Radwanski E, Batra V, Cayen M, Korduba C, Cutler D, Affrime M, et al. Pharmacokinetics of isepamicin following a single administration by intravenous infusion or intramuscular injections. Antimicrob Agents Chemother 1997; 41: 1794-1796 (Pubitemid 27339889)
84. Jones RN Isepamicin (SCH 21420, 1-N-HAPA gentamicin B): microbiological characteristics including antimicrobial potency of spectrum of activity. J Chemother 1995; 7: 7-16.
85. Barr WH, Colucci R, Radwanski E, Zampaglione N, Cutler D, Lin CC, et al. Pharmacokinetics of isepamicin. J Chemother 1995; 7: 53-61.
86. Tod M, Minozzi C, Beaucaire G, Ponsonnet D, Cougnard J, Petitjean O. Isepamicin in intensive care unit patients with Nosocomial pneumonia: population pharmacokinetic-pharmacodynamic study. J Antimicrob Chemother 1999; 44: 99-108.
87. Belgian Isepamicin Multicenter Study Group Comparative in vitro activity of isepamicin and other antibiotics against gram-negative bacilli from intensive care units (ICU) in Belgium. Acta Clin Belg 2001; 56 : 307-315
88. Colardyn F. The efficacy and safety of isepamicin and ceftazidime compared with amikacin and ceftazidime in acute lower respiratory tract infection. J Chemother 1995; 7: 129-135
89. Cheng NC, Hsueh PR, Liu YC, Shyr JM, Huang WK, Teng LJ, et al. In vitro activities of tigecycline, ertapenem, isepamicin, and other antimicrobial agents against clinically isolated organisms in Taiwan. Microb Drug Resist 2005; 11: 330-341
90. Falagas ME, Kopterides P Old antibiotics for infections in critically ill patients. Curr Opin Crit Care 2007; 13: 592-597 (Pubitemid 47357463)
91. Koup JR, Brodsky B, Lau A, Beam TR Jr High-performance liquid chromatographic assay of chloramphenicol in serum. Antimicrob Agents Chemother 1978; 14: 439-443 (Pubitemid 9027815)
92. Glazko AJ, Wolf LM. Biochemical studies on chloramphenicol; tissue distribution and excretion studies. J Pharmacol Exp Ther 1949; 96: 445-459
93. Rich ML, Ritterhoff RJ, Hoffmann RJ A fatal case of aplastic anemia following chloramphenicol (chloromycetin) therapy. Ann Intern Med 1950; 33: 1459-1467
94. Lautenbach E, Schuster MG, Bilker WB, Brennan PJ. The role of chloramphenicol in the treatment of bloodstream infection due to vancomycin-resistant Enterococcus. Clin Infect Dis 1998; 27: 1259-1265 (Pubitemid 29242481)
95. Assefa A, Asrat D, Woldeamanuel Y, G/Hiwot Y, Abdella A, Melesse T. Bacterial profile and drug susceptibility pattern of urinary tract infection in pregnant women at Tikur Anbessa Specialized Hospital Addis Ababa, Ethiopia. Ethiop Med J 2008; 46: 227-235
96. Scapellato PG, Ormazabal C, Scapellato JL, Bottaro EG Meningitis due to vancomycin-resistant Enterococcus faecium successfully treated with combined intravenous and intraventricular chloramphenicol. J Clin Microbiol 2005; 43: 3578-3579
97. Gupta V, Kaur J, Chander J An increase in enteric fever cases due to Salmonella paratyphi A in & around Chandigarh. Indian J Med Res 2009; 129: 95-98
98. Long, James W. Essential Guide to Prescription Drugs 1992, New York, HarperCollins Publishers, 1991. pp. 925-929.
99. Song JY, Lee J, Heo JY, Noh JY, Kim WJ, Cheong HJ, et al. Colistin and rifampicin combination in the treatment of ventilator-associated pneumonia caused by carbapenem-resistant Acinetobacter baumannii. Int J Antimicrob Agents 2008; 32(3): 281-284
100. Motaouakkil S, Charra B, Hachimi A, Nejmi H, Benslama A, Elmdaghri N, et al. Colistin and rifampicin in the treatment of nosocomial infections from multiresistant Acinetobacter baumannii. J Infect 2006; 53(4): 274-278
101. Bassetti M, Repetto E, Righi E, Boni S, Diverio M, Molinari MP, et al. Colistin and rifampicin in the treatment of multidrug-resistant Acinetobacter baumannii infections. J Antimicrob Chemother 2008; 61: 417-420
102. López-Fabal F, Culebras E, Bonilla I, Gómez M, Picazo JJ. [In vitro activities of colistin combinations against Pseudomonas aeruginosa isolated from the intensive care unit]. Rev Esp Quimioter 2008; 21: 189-193
103. Verbist L. The antimicrobial activity of fusidic acid. J Antimicrob Chemother 1990; 25: 1-5.
104. Collignon P, Turnidge J. Fusidic acid in vitro activity. Int J Antimicrob Agents 1999; 12: S45-58.
105. Whitby M. Fusidic acid in the treatment of methicillin-resistant Staphylococcus aureus. Int J Antimicrob Agents 1999; 12 Suppl 2: S67-71.
106. Howden BP, Ward PB, Charles PG, Korman TM, Fuller A, du Cros P, et al. Treatment outcomes for serious infections caused by methicillin-resistant Staphylococcus aureus with reduced vancomycin susceptibility. Clin Infect Dis 2004; 38: 521-528
107. Dobie D, Gray J. Fusidic acid resistance in Staphylococcus aureus Arch Dis Child. 2004; 89: 74-77
108. Howden BP, Ward PB, Charles PG, Korman TM, Fuller A, du Cros P, et al. Treatment outcomes for serious infections caused by methicillin-resistant Staphylococcus aureus with reduced vancomycin susceptibility. Clin Infect Dis 2004; 38: 521-528